Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab
| dc.rights.license | open | en_US |
| dc.contributor.author | STRIZZOLO, Rémi | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | SENESCHAL, Julien | |
| dc.contributor.author | SORIA, Angèle | |
| dc.contributor.author | STAUMONT-SALLÉ, Delphine | |
| dc.contributor.author | BARBAROT, Sébastien | |
| dc.contributor.author | VIGUIER, Manuelle | |
| dc.contributor.author | JACHIET, Marie | |
| dc.contributor.author | NOSBAUM, Audrey | |
| dc.contributor.author | CLÉMENT, Aude | |
| dc.contributor.author | TAUBER, Marie | |
| dc.contributor.author | MALLET, Stéphanie | |
| dc.contributor.author | DU-THANH, Aurélie | |
| dc.date.accessioned | 2025-01-16T15:00:23Z | |
| dc.date.available | 2025-01-16T15:00:23Z | |
| dc.date.issued | 2024-07 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/204327 | |
| dc.description.abstractEn | n patients with moderate to severe atopic dermatitis (AD) showing an inadequate response to dupilumab 300mg/2weeks, few real-life studies reported the response to alternative regimen maintaining dupilumab. To assess and analyze the response to an increased dose of dupilumab or its combination with cyclosporin A (CsA), methotrexate (MTX), or itraconazole (ITRA), all adult AD patients from 7 French University Hospitals were retrospectively included if they achieved an inadequate response to dupilumab 300mg/2weeks and were subsequently treated with an increased dose of dupilumab (300mg every 7 or 10 days), or a combination of dupilumab 300mg/2weeks with CsA, MTX or ITRA. The response after 3 months, along with epidemiological, clinical, and therapeutic baseline characteristics, were collected. Overall, 68.75% of the 48 included patients achieved an improved response, including 45.8% of complete response (CR). No strategy proved significantly better. Patients showing an initial no response never achieved a further CR versus 52.4% of patients with an initial partial response (p = 0.025). Digestive intolerance and tachycardia led to MTX and ITRA discontinuation in 3 patients. Increasing the dose of dupilumab or combining it with CsA, MTX, or ITRA could be alternative and safe options, to be evaluated in further medico-economic studies. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Dermatitis | |
| dc.subject.en | Atopic | |
| dc.subject.en | Dupilumab | |
| dc.subject.en | Cyclosporine | |
| dc.subject.en | Methotrexate | |
| dc.subject.en | Itraconazole | |
| dc.title.en | Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.waojou.2024.100923 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 39157196 | en_US |
| bordeaux.journal | World Allergy Organization Journal | en_US |
| bordeaux.volume | 17 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 7 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| dc.rights.cc | CC BY-NC-ND | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=World%20Allergy%20Organization%20Journal&rft.date=2024-07&rft.volume=17&rft.issue=7&rft.au=STRIZZOLO,%20R%C3%A9mi&SENESCHAL,%20Julien&SORIA,%20Ang%C3%A8le&STAUMONT-SALL%C3%89,%20Delphine&BARBAROT,%20S%C3%A9bastien&rft.genre=article |